BACKGROUND: Specific matrix metalloproteinases (MMP-2, MMP-9) and inflammatory biomarkers (hsCRP, IL-6) were found to be consistently up-regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failure patients. The aim of the present study was to examine the prognostic value of biomarkers of cardiac inflammation and remodeling processes in predicting mortality in patients with MR undergoing percutaneous mitral valve repair (PMVR). HYPOTHESIS: We hypothesize that increased cardiac inflammation and extracellular matrix turnover is predictive for mortality in patients with severe mitral regurgitation undergoing MitraClip. METHODS: A total of 210 consecutive patients undergoing PMVR were included. PMVR was performed according to standard clinical practice. Venous blood samples for biomarker analyses were collected prior to and 6 months after PMVR. Physiological parameters, medication use, safety events, and all-cause mortality were followed over 12 months. RESULTS: PMVR was performed successfully in all patients. Twelve months after PMVR there was an effective reduction in the severity of MR (P < 0.001), and an improvement in New York Heart Association class (P < 0.01) was documented. Elevated inflammatory biomarkers (AUChsCRP : 0.738 [IQR, 0.626-0.849], P = 0.001; AUCIL-6 : 0.811 [IQR, 0.724-0.899], P = 0.001) and biomarkers reflecting cardiac remodeling processes (AUCMMP-2 : 0.723 [IQR, 0.641-0.804], P = 0.001; AUCMMP-9 : 0.618 [IQR, 0.534-0.701], P = 0.01) were predictors of adverse cardiac events and mortality in patients with congestive heart failure undergoing PMVR. CONCLUSIONS: The present study is the first to identify biomarkers reflecting inflammation (hsCRP, IL-6) and cardiac remodeling processes (MMP-2, MMP-9) as predictors of mortality in high-risk patients undergoing PMVR.
BACKGROUND: Specific matrix metalloproteinases (MMP-2, MMP-9) and inflammatory biomarkers (hsCRP, IL-6) were found to be consistently up-regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failurepatients. The aim of the present study was to examine the prognostic value of biomarkers of cardiac inflammation and remodeling processes in predicting mortality in patients with MR undergoing percutaneous mitral valve repair (PMVR). HYPOTHESIS: We hypothesize that increased cardiac inflammation and extracellular matrix turnover is predictive for mortality in patients with severe mitral regurgitation undergoing MitraClip. METHODS: A total of 210 consecutive patients undergoing PMVR were included. PMVR was performed according to standard clinical practice. Venous blood samples for biomarker analyses were collected prior to and 6 months after PMVR. Physiological parameters, medication use, safety events, and all-cause mortality were followed over 12 months. RESULTS: PMVR was performed successfully in all patients. Twelve months after PMVR there was an effective reduction in the severity of MR (P < 0.001), and an improvement in New York Heart Association class (P < 0.01) was documented. Elevated inflammatory biomarkers (AUChsCRP : 0.738 [IQR, 0.626-0.849], P = 0.001; AUCIL-6 : 0.811 [IQR, 0.724-0.899], P = 0.001) and biomarkers reflecting cardiac remodeling processes (AUCMMP-2 : 0.723 [IQR, 0.641-0.804], P = 0.001; AUCMMP-9 : 0.618 [IQR, 0.534-0.701], P = 0.01) were predictors of adverse cardiac events and mortality in patients with congestive heart failure undergoing PMVR. CONCLUSIONS: The present study is the first to identify biomarkers reflecting inflammation (hsCRP, IL-6) and cardiac remodeling processes (MMP-2, MMP-9) as predictors of mortality in high-risk patients undergoing PMVR.
Authors: Colette E Jackson; Caroline Haig; Paul Welsh; Jonathan R Dalzell; Ioannis K Tsorlalis; Alex McConnachie; David Preiss; Stefan D Anker; Naveed Sattar; Mark C Petrie; Roy S Gardner; John J V McMurray Journal: Eur J Heart Fail Date: 2016-04-25 Impact factor: 15.534
Authors: Olaf Franzen; Stephan Baldus; Volker Rudolph; Sven Meyer; Malgorzata Knap; Dietmar Koschyk; Hendrik Treede; Achim Barmeyer; Joachim Schofer; Angelika Costard-Jäckle; Michael Schlüter; Hermann Reichenspurner; Thomas Meinertz Journal: Eur Heart J Date: 2010-03-10 Impact factor: 29.983
Authors: Omar F AbouEzzeddine; Paul M McKie; Christopher G Scott; Richard J Rodeheffer; Horng H Chen; G Michael Felker; Allan S Jaffe; John C Burnett; Margaret M Redfield Journal: Eur J Heart Fail Date: 2016-11 Impact factor: 15.534
Authors: Bernard Iung; Gabriel Baron; Eric G Butchart; François Delahaye; Christa Gohlke-Bärwolf; Olaf W Levang; Pilar Tornos; Jean-Louis Vanoverschelde; Frank Vermeer; Eric Boersma; Philippe Ravaud; Alec Vahanian Journal: Eur Heart J Date: 2003-07 Impact factor: 29.983
Authors: Ted Feldman; Saibal Kar; Michael Rinaldi; Peter Fail; James Hermiller; Richard Smalling; Patrick L Whitlow; William Gray; Reginald Low; Howard C Herrmann; Scott Lim; Elyse Foster; Donald Glower Journal: J Am Coll Cardiol Date: 2009-08-18 Impact factor: 24.094
Authors: Sven T Pleger; Marius Schulz-Schönhagen; Nicolas Geis; Derliz Mereles; Emmanuel Chorianopoulos; Muliadi Antaredja; Markus Lewening; Hugo A Katus; Raffi Bekeredjian Journal: Eur J Heart Fail Date: 2013-03-19 Impact factor: 15.534
Authors: Eve-Marie A Benson; Martin Tibuakuu; Di Zhao; Akintunde O Akinkuolie; James D Otvos; Daniel A Duprez; David R Jacobs; Samia Mora; Erin D Michos Journal: Clin Cardiol Date: 2018-11-19 Impact factor: 2.882